{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:31:18Z","timestamp":1793727078818,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40265-015-0368-z","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T05:11:15Z","timestamp":1425532275000},"page":"439-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Vonoprazan: First Global Approval"],"prefix":"10.1007","volume":"75","author":[{"given":"Karly P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,6]]},"reference":[{"issue":"6","key":"368_CR1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11894-010-0149-5","volume":"12","author":"G Sachs","year":"2010","unstructured":"Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep. 2010;12(6):437\u201347.","journal-title":"Curr Gastroenterol Rep."},{"issue":"5","key":"368_CR2","doi-asserted-by":"crossref","first-page":"e97688","DOI":"10.1371\/journal.pone.0097688","volume":"9","author":"HJ Luo","year":"2014","unstructured":"Luo HJ, Deng WQ, Zou K. Protonated form: the potent form of potassium-competitive acid blockers. PLoS One. 2014;9(5):e97688.","journal-title":"PLoS One."},{"issue":"2","key":"368_CR3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412\u201320.","journal-title":"J Pharmacol Exp Ther."},{"key":"368_CR4","unstructured":"Takeda. New drug application approval of TAKECAB\u00ae for the treatment of acid-related diseases in Japan (media release). 26 Dec 2014. http:\/\/www.takeda.com ."},{"key":"368_CR5","unstructured":"Takeda. Takeda submits a new drug application for TAK-438 in Japan for the treatment of acid-related diseases (media release). 28 Feb 2014. http:\/\/www.takeda.co.jp ."},{"key":"368_CR6","unstructured":"Takeda. ClinicalTrials.gov. 2014. http:\/\/www.clinicaltrials.gov\/ . Accessed 30 Jan 2015."},{"key":"368_CR7","unstructured":"Otsuka Pharmaceutical, Takeda Pharmaceutical Company Limited. Otsuka and Takeda announce a co-promotion agreement in Japan of TAK-438 for the treatment of acid-related diseases in the gastrointestinal therapeutic area (media release). 2014. http:\/\/www.otsuka.co.jp . Accessed 27 Mar 2014."},{"issue":"1","key":"368_CR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231\u20138.","journal-title":"J Pharmacol Exp Ther."},{"key":"368_CR9","unstructured":"Takeda. Takecab\u00ae (vonoprazan tablets): Japanese prescribing information. 2014. http:\/\/www.takedamed.com\/content\/medicine\/pdf\/pre-takecab.pdf . Accessed 5 Feb 2015."},{"issue":"9","key":"368_CR10","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/jm300318t","volume":"55","author":"Y Arikawa","year":"2012","unstructured":"Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55(9):4446\u201356.","journal-title":"J Med Chem."},{"key":"368_CR11","doi-asserted-by":"crossref","unstructured":"Mizokami Y, Ashida K, Soen S, et al. TAK-438 vs. lansoprazole 15\u00a0mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial [abstract no. Tu1054]. Gastroenterology. 2014;146(5 Suppl. 1):S-739.","DOI":"10.1016\/S0016-5085(14)62677-9"},{"key":"368_CR12","doi-asserted-by":"crossref","unstructured":"Kawai T, Ashida K, Mizokami Y, et al. TAK-438 vs. lansoprazole 15\u00a0mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial (abstract no. Tu1055). Gastroenterology. 2014;146(5 Suppl. 1):S-739.","DOI":"10.1016\/S0016-5085(14)62678-0"},{"key":"368_CR13","doi-asserted-by":"crossref","unstructured":"Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20\u00a0mg once-daily) compared to lansoprazole (30\u00a0mg once-daily) in patients with erosive esophagitis (abstract no. Tu1059). Gastroenterology. 2014;146(5 Suppl. 1):S-741.","DOI":"10.1016\/S0016-5085(14)62682-2"},{"key":"368_CR14","doi-asserted-by":"crossref","unstructured":"Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10\u00a0mg or 20\u00a0mg once-daily) compared to lansoprazole (15\u00a0mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis (abstract no. Tu1052). Gastroenterology. 2014;146(5 Suppl. 1):S-738.","DOI":"10.1016\/S0016-5085(14)62675-5"},{"key":"368_CR15","doi-asserted-by":"crossref","unstructured":"Chiba T, Sakurai Y, Nishimura A, et al. A phase 2, randomized, double-blind, parallel-group, multicenter, dose-ranging study to evaluate the efficacy and safety of a novel potassium-competitive acid blocker (P-CAB) TAK-438 in patients with erosive esophagitis (abstract no. Mo1053). Gastroenterology. 2013;144(5 Suppl. 1):S-564-5.","DOI":"10.1016\/S0016-5085(13)62088-0"},{"issue":"Suppl 1","key":"368_CR16","first-page":"79","volume":"19","author":"K Murakami","year":"2014","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. A newly developed potassium-competitive acid blocker, vonoprazan vs. Lansoprazole in first-line triple therapy with amoxicillin, and clarithromycin for H. pylori eradication\u2014phase 3, double-blind study (abstract no. W2.2). Helicobacter. 2014;19(Suppl 1):79.","journal-title":"Helicobacter"},{"key":"368_CR17","doi-asserted-by":"crossref","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy With TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori (abstract no. Tu1056). Gastroenterology. 2014;146(5 Suppl. 1):S-740.","DOI":"10.1016\/S0016-5085(14)62679-2"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0368-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0368-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0368-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:41Z","timestamp":1559490101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0368-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0368-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}